ArticleProbiotics and antimicrobial proteins2026
Lacticaseibacillus rhamnosus BELR47 Mitigates Inflammatory Response in a Gardnerella vaginalis-Induced Bacterial Vaginosis Mouse Model via Gut Microbiome Modulation.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Targeting the gut to heal the skin: probiotic supplementation reduces wound infection risk and clinical burden in critically ill patients-a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- Safety Assessment of Lacticaseibacillus rhamnosus OF44, a Previously Isolated Human-origin Probiotic Candidate.Current microbiology · 2026Article
- Vaginal Probiotic Potential of the Nomadic Species Limosilactobacacillus fermentum Under Dysbiotic Vaginal Conditions: Population Genomic Insights and Anti-Pathogenic Efficacy of a Vaginal Isolate VL9.Probiotics and antimicrobial proteins · 2026Article
- Shared Gut Microbial and Functional Signatures Linking Parkinson's Disease and Type 2 Diabetes Revealed by Function-Anchored Metagenomics.Microorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, Lacticaseibacillus rhamnosus BELR47 showed the highest lactate production, adhesion to HeLa cells, biofilm formation, and antimicrobial activity against three major bacterial vaginosis (BV)-associated pathogens: Gardnerella vaginalis, Fannyhessea vaginae, and Candida albicans. Moreover, BELR47 exerted anti-inflammatory effects in lipopolysaccharide-induced RAW 264.7 macrophages by suppressing pro-inflammatory cytokine production. In BV-induced mice, oral BELR47 administration significantly reduced vaginal exfoliation and G. vaginalis proliferation compared to the Control group. The Control group exhibited elevated serum interlukin-1β and increased myeloperoxidase, cyclooxygenase 2, inducible nitric oxide synthase, and tumor necrosis factor-alpha mRNA levels in the vagina, cervix, and gut, alongside decreased interlukin-10 expression, which BELR47 treatment reversed. Moreover, G. vaginalis infection diminished colonic expression of tight junction proteins (Claudin-3, Claudin-7, Occludin, ZO-1), indicating impaired gut barrier function; BELR47 ameliorated this dysfunction. BV also reduced fecal microbiome diversity, whereas BELR47 treatment restored it, as reflected by the increased levels of Butyricimonas and Lactobacillus and decreased Parasutterella. Additionally, the elevated butyric acid levels in the BELR47-treated group supported its potential to mitigate gut barrier dysfunction and alleviate intestinal inflammation. Therefore, G. vaginalis infection induces inflammation in both the vagina and colon, disrupts the gut microbiome, and alters fecal metabolites, thereby supporting the concept of a "vagina-gut axis."
Indexed as
Identifiers
41144182What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.